Bristol-myers Squibb Compnay

Other

G.d. Searle & Company

G.d. Searle LLC

James J Li

Jun Li

Joseph Anthony Tino

William R Ewing

Lawrence G Hamann

Haixia Wang

Jeffrey A Robl

Richard B Sulsky

Guixue Yu

David John Augeri

Yingzhi Bi

Lawrence J Kennedy

James Clifford Sutton

Tammy C Wang

Chenkou Wei

Zheming Ruan

Christopher Blair Cooper

Hannguang J Chao

Michael A Galella

Chong-qing Sun

Ligaya Simpkins

Alexandra Holubec

Jie Jack Li

Yan-Ting Huang

David B Reitz

Samuel J Tremont

Monica B Norton

Mark John Pozzo

Jon P Lawson

Claire A Przybyla

Kevin J Koeller

Andres S Hernandez

Stephen P O'Connor

James C Peterson

Xinhua Qian

Payman N Farid

Rajendra P Deshpande

Pierre-Jean Colson

Kevin Babiak

Benxin Zhi

Robert Hett

Grace Mary Wagner

Jay S Trivedi

Shine Chou

Christian H Huber

Gerald A Weisenburger

Andrew Carpenter

Eduardo K Mar

Vladislav Orlovski

Stephen G Swartz

Reginald O Cann

Laxma Reddy Kolla

Lawrence M Miller

Le Qi

Stephen P O'CONNOR

Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R, R', R, R, R, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.

Heterocyclic aromatic compounds useful as growth hormone secretagogues

Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d). 

Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R, R, and Rare defined herein.

Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein R, R, and Rare defined herein. 

1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:W-L-Z&#x2003;&#x2003;(I)or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.

Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R, R, Rand Rare defined herein.

There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.

Bicyclic modulators of androgen receptor function

There are disclosed bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R, R, R, X and n are defined herein.

Bicyclic compounds as modulators of androgen receptor function and method

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R, R, R, X and n are defined herein.

Growing community of inventors

Pennington, NJ, United States of America

James J Li